Table 1 Baseline patient demographics and clinical characteristics of patients undergoing robotic and open lobectomy
From: Robotic lobectomy has the greatest benefit in patients with marginal pulmonary function
Robotic Lobectomy | Open Lobectomy | P-value | |
|---|---|---|---|
(n = 287) | (n = 312) | ||
Age [years], mean ± SD | 65.3 ± 11.3 | 63.2 ± 10.1 | 0.016 |
Male Gender | 134 (47%) | 157 (50%) | 0.41 |
Zubrod Score | |||
0–1 | 270 (94%) | 291 (93%) | 0.67 |
2+ | 17 (6%) | 21 (7%) | |
Pack years, median (IQR) | 40 (21–60) | 40 (23–60) | 0.51 |
Active smoker | 91 (32%) | 92 (30%) | 0.59 |
FEV1 [% predicted], mean ± SD | 82.4 ± 19.7 | 77.6 ± 19.7 | 0.003 |
DLCO [% predicted], mean ± SD | 75.5 ± 22.8 | 74.5 ± 20.2 | 0.59 |
COPD | 128 (45%) | 118 (38%) | 0.09 |
BMI > 30 kg/m2 | 88 (31%) | 100 (32%) | 0.80 |
Hypertension | 180 (63%) | 188 (60%) | 0.56 |
Steroid use | 9 (3%) | 10 (3%) | 0.96 |
Coronary artery disease | 121 (42%) | 132 (42%) | 0.97 |
Peripheral vascular disease | 29 (10%) | 22 (7%) | 0.19 |
Prior cardiothoracic surgery | 40 (14%) | 64 (20%) | 0.040 |
Preoperative chemotherapy | 11 (4%) | 26 (8%) | 0.027 |
Preoperative radiation therapy | 13 (5%) | 25 (8%) | 0.10 |
Diabetes | 45 (16%) | 61 (20%) | 0.22 |
Preoperative creatinine > 1.5 mg/dl | 25 (4%) | 13 (4%) | 0.98 |
Lung cancer | 240 (83%) | 256 (82%) | 0.61 |
Pathologic Stage (AJCC 7th ed.) | |||
Stage I-II | 209 (87%) | 220 (86%) | 0.75 |
Stage III-IVa | 31 (13%) | 35 (14%) | |
Laterality | |||
Left | 176 (61%) | 197 (63%) | 0.65 |
Right | 111 (39%) | 115 (37% | |